Core Viewpoint - The strategic partnership between Optoseeker Biotech and BioMap aims to revolutionize the development of innovative antibody therapies by integrating high-throughput cell screening capabilities with advanced AI systems, thereby accelerating drug discovery processes [2][3]. Group 1: Partnership Details - The collaboration focuses on combining Optoseeker's proprietary OptoBot series, which excels in high-throughput and high-precision single-cell functional screening, with BioMap's AI-driven capabilities in life sciences [2][3]. - The goal is to create a seamless workflow that can identify promising antibody candidates with unprecedented speed and accuracy, addressing critical bottlenecks in drug development [2][3]. Group 2: Technology Overview - The OptoBot series utilizes advanced Optoelectronic Tweezers (OET) technology to rapidly separate, culture, and analyze thousands of antibody-secreting plasma cells simultaneously, generating vast amounts of high-quality functional data [3]. - BioMap's AI system, built on its proprietary life sciences foundational model, is designed to enhance tasks such as task planning, mapping, protein function prediction, and candidate selection [3]. Group 3: Company Profiles - Optoseeker Biotech is dedicated to developing cutting-edge life science instruments to accelerate biological research and development, with a focus on high-throughput single-cell analysis and automation [4]. - BioMap is a pioneer in foundational models for life sciences, boasting a 210 billion parameter biological language model that decodes the underlying principles of genomes, proteins, cells, and biological systems, significantly reducing reliance on traditional experimental models [5].